Patient education should include a detailed description of the treatment day and
posttreatment care, including possible side effects, instructions about radiation safety to …

J of Nuclear Medicine Technology, first published online August 3, 2018 as doi:
10.2967/jnmt. 118.217844 o Laboratory evaluations, including creatinine, glomerular …

177Lu-DOTATATE is a radiolabeled somatostatin analog that has been approved by the US
Food and Drug Administration (FDA) for the treatment of somatostatin receptor–positive …

At Banner MD Anderson Cancer Center in Arizona, we have gained valuable knowledge of
the different infusion methods for 177Lu-DOTATATE peptide receptor radionuclide therapy …

Purpose 177Lu-labelled somatostatin analog DOTATATE is an excellent vector for systemic
radiation therapy in NETs. However, this treatment can affect organ functions or impact the …

Lutetium-177 is increasingly used in patients for receptor-targeted radionuclide therapy with
peptides such as [DOTA0, Tyr3] octreotate. In our therapy facility, we are performing yearly …

Peptide receptor radiotherapy using 177Lu-labeled somatostatin ligand analogs is a well-
established treatment for neuroendocrine tumors, with 177Lu-DOTATATE having acquired …

MATERIALS AND METHODS Systematic Review To inform the development of these
guidelines, a systematic review of evidence was performed. We followed the Preferred …

Rationale: Peptide receptor radionuclide therapy (PRRT) with 177 Lu-DOTATATE
(oxodotreotide) results in external radiation exposure from the patient. In the PREELU …

Purpose Peptide receptor radionuclide therapy (PRRT) is used in tumours expressing type 2
somatostatin receptors (sst 2), mainly neuroendocrine. The aim of this prospective phase I-II …